Improving Pediatric Drug Development

Improving Pediatric Drug Development

More data about the efficacy and safety of drugs in children are needed. Most drug trials are conducted in adults and so their results, including recommended dosing, cannot be translated directly to children. In recent years, federal legislation has required drug companies to do testing to determine dosing in drugs considered for use in children. As a result, the situation has improved for newer drugs. However, the problem persists for older, generic drugs. Andrew M. Atz, M.D., chair of the Department of Pediatrics at the Medical University of South Carolina, recently joined clinical trialists from academic medical centers and representatives from the FDA, drug companies and advocacy groups on a national think tank to address the problem. In this video, Atz outlines the problem and discusses some of the think tank’s recommendations.


Published

May 21, 2018

Created by

The Medical University of South Carolina

Related Presenters

Andrew M. Atz, MD

Andrew M. Atz, MD

Pediatric Cardiology

View full profile